[Correspondence] Rethinking CLDN18.2 expression in gastric cancer therapy

The Article by Changsong Qi and colleagues,1 on satricabtagene autoleucel (satri-cel), a claudin-18 isoform 2 (CLDN18.2) targeted chimeric antigen receptor (CAR) T-cell therapy, is a crucial milestone in addressing therapeutic stagnation in gastric or gastro-oesophageal junction adenocarcinomas. However, the discussion surrounding biomarker-based patient selection, particularly CLDN18.2 expression, warrants deeper scrutiny.